Stratistics Market Research Consulting

Erythropoietin Drug Market Report 2017, Trends, Analysis, Share, Estimates and Forecasts to 2022.

Press Release   •   Aug 08, 2017 01:34 EDT

According to Stratistics MRC, the Global Erythropoietin Drug Market is accounted for $8.04 billion in 2016 and is expected to reach $14.4 billion by 2022 growing at a CAGR of 10.2% from 2016 to 2022. Rising number of chronic kidney diseases (CKD) and dialysis patient pools are the major drivers for the market. Moreover, increasing cases of cancer, HIV‘s and ESRD (End Stage Renal Diseases) are some of the factors enhancing the market growth. However, growing competition from substitute drugs and rising threats from thrombosis and PRCA are the factors inhibiting the market size.

By Application, anemia segment leads the Erythropoietin Drugs market during the forecast period. On the other hand, retail pharmacies in end user segment dominated the global market with a huge market share. In terms of geography, Europe commanded the maximum market share and will continue to dominate the market over the forecast period.

Some of the key players in the market include Johnson and Johnson, Hospira, Inc., F. Hoffmann-La Roche AG, Amgen Inc, Kyowa Hakko Kirin Co., Ltd, 3SBio Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Intas Pharmaceuticals, Dr. Reddy's Laboratories, Teva Pharmaceutical Industries, JCR Pharmaceuticals, LG Life Science, Novartis AG, Shenyang Sunshine Pharmaceutical, Sihuan Pharmaceutical, Uni-Bio Science, Wanbang Biochemical Pharmaceuticals, Pfizer Inc., Chugai Pharmaceutical and Dragon Pharma.

For More, Please Visit: http://www.strategymrc.com/report/erythropoietin-drug-market

Products Covered:
• Biosimilars
o Epoetin-Alfa
o Epoetin-Beta
o Darbepoietin-Alfa
o Other Biosimilar Products
• Biologics
o Epoetin-Zeta
o Epoetin-Omega
• Other Biologic Products

Drugs Covered:
• Biosimilar Drug
o Xue Da Sheng
o HEMAX
o Abseamed
o Retacrit
o Epoetin-alfa BS
o EPIAO
o Binocrit
o Other Biosimilar Drugs
• Biologic Drug
o Aranesp
o Mircera
o Procrit
o NeoRecromon
o Eprex
o Epogen
o Other Biologic Drugs

Applications Covered:
• Anemia
• HIV
• End Stage Renal Disease
• Cancer
• Dialysis
• Oncology Diseases
• Other Applications

End Users Covered:
• Retail Pharmacies
• Hospital
• Other End Users

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o France
o Italy
o UK
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o Rest of Asia Pacific
• Rest of the World
o Middle East
o Brazil
o Argentina
o South Africa
o Egypt

What our report offers:
- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 6 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments

For More, Please Visit: http://www.strategymrc.com/report/erythropoietin-drug-market

We offer wide spectrum of research and consulting services with in-depth knowledge of different industries. We are known for customized research services, consulting services and Full Time Equivalent (FTE) services in the research world. We explore the market trends and draw our insights with valid assessments and analytical views. We use advanced techniques and tools among the quantitative and qualitative methodologies to identify the market trends. Our research reports and publications are routed to help our clients to design their business models and enhance their business growth in the competitive market scenario. We have a strong team with hand-picked consultants including project managers, implementers, industry experts, researchers, research evaluators and analysts with years of experience in delivering the complex projects.